Search clinical trials for: BMS-986256

Total 3165 results

Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Diabetes

United States
Bristol-Myers Squibb

Completed

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

Atherosclerosis

Australia
Bristol-Myers Squibb

Completed

Multiple-Ascending Dose Study

Depression

Sweden
Bristol-Myers Squibb

Completed

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Tumors

United States
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (POETYK-PSO-1)

Psoriasis

China, Korea, Republic of, Spain, United States, United Kingdom, Canada, Russian Federation, Japan, Germany, Poland, Taiwan
Bristol-Myers Squibb

Completed

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Advanced Solid Tumors | Advanced B-cell NHL

United States, France, Spain, Germany
Bristol-Myers Squibb

Completed

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb

Completed

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

Thrombosis

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

Cancer (Solid Tumors)

United Kingdom, United States, Canada
Bristol-Myers Squibb

Terminated

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)

Advanced Solid Tumors

United States, Netherlands
Bristol-Myers Squibb

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Immunosuppression For Disease
Bristol-Myers Squibb

Terminated

Safety and Pharmacology Study of BMS-866949

Major Depression

Sweden
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects

Depression

Sweden
Bristol-Myers Squibb

Completed

Single Dose Study of BMS-820836

Depression

Canada
Bristol-Myers Squibb

Completed

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

Heart Diseases

United States
National Cancer Institute (NCI)

Terminated

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
Bristol-Myers Squibb

Terminated

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Canada
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Pan Tumor

United States, Puerto Rico, Italy, Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Netherlands, Poland, Romania, Singapore, Spain, United Kingdom
Bristol-Myers Squibb
Yale University

Completed

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate 592)

Non-Small Cell Lung Cancer

Belgium, Italy, United States, France, Germany, Netherlands, Spain, Romania
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)

Renal Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostrate Cancer

United States
Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)

France, Korea, Republic of, Taiwan, United States, Singapore, Philippines, Malaysia, Hong Kong
Bristol-Myers Squibb

Completed

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, United States, Australia
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Chronic Hepatitis C

United States, Argentina
Bristol-Myers Squibb

Terminated

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Hypercholesterolemia

Germany, Canada
Leonardo Bolognese, MD

Terminated

A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation (ELICOPTER)

Myocardial Ischemia

Italy
Georgetown University
Bristol-Myers Squibb; M.D. Anderson Cancer Center; University of Colorado, Denver and other collaborators

Terminated

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma | Acral Lentiginous Melanoma

United States
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)

Kidney Neoplasms

India
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Healthy Adult Normals

United States
Hackensack Meridian Health

Terminated

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)

Acute Myeloid Leukemia and Myelodysplastic Syndrome

United States
Boston Scientific Corporation

Completed

PROPPER Prospective Registry of Outcomes With Penile Prosthesis (PROPPER)

Erectile Dysfunction | Impotence

United States, Canada
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

HIV Infections

United States
R-Pharm

Completed

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Metastatic Breast Cancer
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States

3

Subscribe